Ypsomed Holding AG
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a YPHDF research report →
Companywww.ypsomed.com
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates in two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, patch injectors, and wearable injectors, as well as other smart devices.
- CEO
- Simon Michel
- IPO
- 2022
- Employees
- 2,600
- HQ
- Burgdorf, CH
Price Chart
Valuation
- Market Cap
- $4.84B
- P/E
- 23.41
- P/S
- 5.77
- P/B
- 5.63
- EV/EBITDA
- 16.78
- Div Yield
- 0.66%
Profitability
- Gross Margin
- 41.25%
- Op Margin
- 18.71%
- Net Margin
- 24.63%
- ROE
- 26.86%
- ROIC
- 13.73%
Growth & Income
- Revenue
- $748.87M · 36.54%
- Net Income
- $87.50M · 11.66%
- EPS
- $6.41 · 11.67%
- Op Income
- $112.85M
- FCF YoY
- -301.86%
Performance & Tape
- 52W High
- $535.75
- 52W Low
- $354.92
- 50D MA
- $359.89
- 200D MA
- $414.58
- Beta
- 0.74
- Avg Volume
- 22.524
Get TickerSpark's AI analysis on YPHDF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our YPHDF Coverage
We haven't published any research on YPHDF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate YPHDF Report →